




UNITED STATES
PATENT AND
TRADEMARK OFFICE



Commissioner for Patents
Washington, DC 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/079,130	02/20/2002	Richard B. Meagher	21099.0074U2

CONFIRMATION NO. 6995

David G. Perryman, Esq.
NEEDLE & ROSENBERG, P.C.
The Candler Building, Suite 1200
127 Peachtree Street, N.E.
Atlanta, GA 30303-1811

FORMALITIES LETTER



OC000000009607937

Date Mailed: 03/06/2003

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Filing Date Granted


Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- o This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- o For Rules Interpretation, call (703) 308-4216
- o To Purchase PatentIn Software, call (703) 306-2600
- o For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



0300
Box 899
Attorney Docket No. 210969.0074U2
Serial No. 10/079,130

**ATTORNEY DOCKET NO. 21099.0074U2
PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)	
)	
Meagher et al.)	Group Art Unit: Unassigned
)	
Serial No. 10/079,130)	Examiner: Unassigned
)	
Filed: February 20, 2002)	Confirmation No. 6995
)	
For: RAPID PRODUCTION OF)	
MONOCLONAL ANTIBODIES)	

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO
ACID SEQUENCE DISCLOSURES**

Mail Stop: Sequence
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

NEEDLE & ROSENBERG, P.C.
Customer No. 23859

May 6, 2003

Sir:

This is in response to the Communication dated March 6, 2003. A copy of this document is enclosed. Please amend the application as follows.